- Investing.com
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Strategic Opportunities | Delve into Baxter's potential for expansion in emerging markets and innovation in digital health, leveraging its established position to drive long-term growth |
Future Outlook | Analyst targets range from $30 to $57.82, reflecting optimism about Baxter's 2025 guidance and ability to capitalize on favorable industry trends |
Market Position | Explore Baxter's significant role in the U.S. Medical Supplies & Devices sector, serving diverse healthcare facilities and maintaining a strong market presence |
Resilient Performance | Baxter International navigates challenges in the medical supplies sector, showing resilience with projected net income growth and positive EPS forecasts for FY2025 |

Metrics to compare | BAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.1x | 25.6x | −0.5x | |
PEG Ratio | 0.08 | 0.06 | 0.00 | |
Price / Book | 1.6x | 1.5x | 2.6x | |
Price / LTM Sales | 1.0x | 1.6x | 3.3x | |
Upside (Analyst Target) | −0.8% | 0.0% | 45.0% | |
Fair Value Upside | Unlock | 46.4% | 5.1% | Unlock |